Magrolimab Achieves Positive Results in Ongoing Phase 1b Trial

Magrolimab Achieves Positive Results in Ongoing Phase 1b Trial

284845

Magrolimab Achieves Positive Results in Ongoing Phase 1b Trial

Gilead Sciences’ investigational therapy magrolimab was well-tolerated and effective in untreated acute myeloid leukemia (AML) patients ineligible for intensive chemotherapy, according to data from a Phase 1b trial. These results were presented recently in an oral presentation, titled “The First-in-Class Anti-CD47 Antibody Magrolimab Combined with Azacitidine Is Well-Tolerated and Effective in AML Patients: Phase 1b Results,” at the 62nd American Society of Hematology Annual Meeting and Exposition. “In this ongoing study, treatment with magrolimab and…

You must be logged in to read/download the full post.